Loading stock…

Amneal Pharmaceuticals, Inc. (AMRX) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Amneal Pharmaceuticals, Inc.

AMRXMarket cap $6.84BPrice $19.6

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Manufactures generic and specialty drugs, cranking out billions of pills a year across injectables, oral solids, and biosimilars. It's one of the largest generics makers in the US, quietly filling prescriptions behind countless pharmacy counters.

In Bastion Portfolios?

52W Return+98%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+5%4

Rev CAGR (3y)+8%6

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+1+339%10

EPS Growth Y+2+23%8

EPS Growth Y+3+19%8

Quality

Margins

EBIT Margin16%6

Net Income Margin5%4

Free Cash Flow Margin3%3

Debt

Net Debt/EBITDA3.82

Efficiency

ROE953%10

ROA6%7

Earnings Stability44

GEAR+AVERAGE49

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)204

P/E Ratio (Forward 3y)135

P/BV207.21

EV Multiples

EV/EBITDA Fwd135

EV/EBIT Fwd146

Yield

Free Cash Flow Yield1.2%3

Dividend Yieldna–

Momentum

Short term

1 month return+15%10

3 month return+16%9

YTD return+56%9

Mid term

Price vs 52wHigh93%9

1 year return+88%10

Long term

3 year return+369%10

5 year return+250%9

Risk Shield

Price Risk

Beta0.76

Volatility36%5

Free Cash Flow

Free Cash Flow Margin3%3

Free Cash Flow Yield1.2%3

Quality

ROCE19%8

Earnings Stability44

Net Debt/EBITDA3.82

02Growth

Is it actually growing, and how fast?

AMRXAmneal Pharmaceuticals

Revenue FY25$3.0B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+339%10

EPS growth, FY27E+23%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 23%/yr vs revenue 8%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG98 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+16%9

YTD return+56%9

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+88%10

3-year return+369%10

5-year return+250%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +369% over three years and +250% over five, ahead of 90% of the market.

It's up 88% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+16%) and so far this year (+56%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Amneal Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AMRXAmneal Pharmaceuticals

Revenue FY25$3.0B

GROWTH RATING↗

AVERAGE62 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+5%4

Revenue, next 3Y, CAGR+8%6

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+339%10

EPS growth, FY27E+23%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 23%/yr vs revenue 8%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 62% of companies worldwide.

Revenue is set to grow 8%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 11%/yr over the last 3 years and is set to keep growing around 8%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG98 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+16%9

YTD return+56%9

MID & LONG-TERM▾SCORE

% of 52-week high93%9

1-year return+88%10

3-year return+369%10

5-year return+250%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +369% over three years and +250% over five, ahead of 90% of the market.

It's up 88% over the past year, now 7% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+16%) and so far this year (+56%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Amneal Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community